Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • Febuxostat improves...

    Febuxostat improves hyperlipidemia in addition to lowering uric acid in gout patients

    Written by Medha Baranwal Baranwal Published On 2019-08-01T20:10:47+05:30  |  Updated On 1 Aug 2019 8:10 PM IST
    Febuxostat improves hyperlipidemia in addition to lowering uric acid in gout patients

    China: Febuxostat -- Uric acid‐lowering therapy (UALT) therapy in gout patients improves serum cholesterol and triglyceride levels compared to allopurinol and benzbromarone, according to a recent study published in the International Journal of Rheumatic Diseases.


    Gout is the most common inflammatory arthritis affecting 2.4% of adults and typically affects older populations. It is caused by the accumulation of uric acid in the joint. Gouty patients have high levels of hypercholesterolemia and hypertriglyceridemia, and gout control may benefit from cholesterol and triglyceride therapy.


    The most common urate‐lowering medication, allopurinol, causes severe and frequent adverse reactions, including Stevens-Johnson syndrome and drug hypersensitivity syndrome. Benzbromarone is a popular treatment option in China, however, it is not recommended for patients with liver and renal insufficiency due to its high metabolism in the liver. Febuxostat is a non‐purine xanthine oxidase inhibitor that is approved in China, Europe and the U.S. for gout treatment. The safety and efficacy of febuxostat have been shown in may studies, but there is limited information on its effectiveness in gouty patients with hypertriglyceridemia or hypercholesterolemia.


    Jing Wu, Zhujiang Hospital, Southern Medical University, Guangzhou, China, and colleagues conducted the study to investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid‐lowering therapy.


    The researchers performed a retrospective study from January 2015 to December 2017 in gouty patients receiving UALT. 124 gouty patients with hypercholesterolemia or hypertriglyceridemia who received UALT were monitored.


    A total of 52, 29 and 43 patients were treated with febuxostat, allopurinol, and benzbromarone, respectively, and their efficiency was compared. Cholesterol and triglyceride levels were recorded and analyzed following treatment for 8‐10 weeks.


    Also Read: Gout patients at increased risk of VTE independent of urate-lowering therapy

    Key findings of the study include:

    • Every UALT therapy mildly influenced serum cholesterol and triglyceride levels.

    • Febuxostat significantly decreased cholesterol and triglyceride levels in patients who did not receive lipid‐lowering therapy.

    • Allopurinol and benzbromarone modestly decreased triglyceride levels, but cholesterol levels were unaffected.


    Also Read: Despite readily available treatment, gout remains under-treated, finds study

    "In gouty patients, uric acid-lowering therapy benefited hyperlipidemia. In comparison with allopurinol and benzbromarone, febuxostat efficiently improved serum cholesterol and triglyceride levels in patients with gout," concluded the authors.


    To read the complete study log on to https://doi.org/10.1111/1756-185X.13652
    benzbromaronecholesterolFebuxostatGoutHypercholesterolemiahyperlipidemiaHypertriglyceridemiaInternational Journal of Rheumatic DiseasesJing WujointMedical newsrecent medical newsserum cholesteroltriglycerideUALTuric aciduric acid lowering therapy

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok